Hdl Handle:
http://hdl.handle.net/10147/206357
Title:
Gene therapy for prostate cancer.
Authors:
Tangney, Mark; Ahmad, Sarfraz; Collins, Sara A; O'Sullivan, Gerald C
Affiliation:
Cork Cancer Research Centre, Mercy University Hospital, Cork, Ireland., m.tangney@ucc.ie
Citation:
Postgrad Med. 2010 May;122(3):166-80.
Journal:
Postgraduate medicine
Issue Date:
31-Jan-2012
URI:
http://hdl.handle.net/10147/206357
DOI:
10.3810/pgm.2010.05.2154
PubMed ID:
20463426
Abstract:
Cancer remains a leading cause of morbidity and mortality. Despite advances in understanding, detection, and treatment, it accounts for almost one-fourth of all deaths per year in Western countries. Prostate cancer is currently the most commonly diagnosed noncutaneous cancer in men in Europe and the United States, accounting for 15% of all cancers in men. As life expectancy of individuals increases, it is expected that there will also be an increase in the incidence and mortality of prostate cancer. Prostate cancer may be inoperable at initial presentation, unresponsive to chemotherapy and radiotherapy, or recur following appropriate treatment. At the time of presentation, patients may already have metastases in their tissues. Preventing tumor recurrence requires systemic therapy; however, current modalities are limited by toxicity or lack of efficacy. For patients with such metastatic cancers, the development of alternative therapies is essential. Gene therapy is a realistic prospect for the treatment of prostate and other cancers, and involves the delivery of genetic information to the patient to facilitate the production of therapeutic proteins. Therapeutics can act directly (eg, by inducing tumor cells to produce cytotoxic agents) or indirectly by upregulating the immune system to efficiently target tumor cells or by destroying the tumor's vasculature. However, technological difficulties must be addressed before an efficient and safe gene medicine is achieved (primarily by developing a means of delivering genes to the target cells or tissue safely and efficiently). A wealth of research has been carried out over the past 20 years, involving various strategies for the treatment of prostate cancer at preclinical and clinical trial levels. The therapeutic efficacy observed with many of these approaches in patients indicates that these treatment modalities will serve as an important component of urological malignancy treatment in the clinic, either in isolation or in combination with current approaches.
Language:
eng
MeSH:
Animals; *Gene Therapy; Genetic Vectors; Humans; Immunotherapy; Male; Mice; Prostatic Neoplasms/*therapy
ISSN:
1941-9260 (Electronic); 0032-5481 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorTangney, Marken_GB
dc.contributor.authorAhmad, Sarfrazen_GB
dc.contributor.authorCollins, Sara Aen_GB
dc.contributor.authorO'Sullivan, Gerald Cen_GB
dc.date.accessioned2012-01-31T16:38:23Z-
dc.date.available2012-01-31T16:38:23Z-
dc.date.issued2012-01-31T16:38:23Z-
dc.identifier.citationPostgrad Med. 2010 May;122(3):166-80.en_GB
dc.identifier.issn1941-9260 (Electronic)en_GB
dc.identifier.issn0032-5481 (Linking)en_GB
dc.identifier.pmid20463426en_GB
dc.identifier.doi10.3810/pgm.2010.05.2154en_GB
dc.identifier.urihttp://hdl.handle.net/10147/206357-
dc.description.abstractCancer remains a leading cause of morbidity and mortality. Despite advances in understanding, detection, and treatment, it accounts for almost one-fourth of all deaths per year in Western countries. Prostate cancer is currently the most commonly diagnosed noncutaneous cancer in men in Europe and the United States, accounting for 15% of all cancers in men. As life expectancy of individuals increases, it is expected that there will also be an increase in the incidence and mortality of prostate cancer. Prostate cancer may be inoperable at initial presentation, unresponsive to chemotherapy and radiotherapy, or recur following appropriate treatment. At the time of presentation, patients may already have metastases in their tissues. Preventing tumor recurrence requires systemic therapy; however, current modalities are limited by toxicity or lack of efficacy. For patients with such metastatic cancers, the development of alternative therapies is essential. Gene therapy is a realistic prospect for the treatment of prostate and other cancers, and involves the delivery of genetic information to the patient to facilitate the production of therapeutic proteins. Therapeutics can act directly (eg, by inducing tumor cells to produce cytotoxic agents) or indirectly by upregulating the immune system to efficiently target tumor cells or by destroying the tumor's vasculature. However, technological difficulties must be addressed before an efficient and safe gene medicine is achieved (primarily by developing a means of delivering genes to the target cells or tissue safely and efficiently). A wealth of research has been carried out over the past 20 years, involving various strategies for the treatment of prostate cancer at preclinical and clinical trial levels. The therapeutic efficacy observed with many of these approaches in patients indicates that these treatment modalities will serve as an important component of urological malignancy treatment in the clinic, either in isolation or in combination with current approaches.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.mesh*Gene Therapyen_GB
dc.subject.meshGenetic Vectorsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunotherapyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiceen_GB
dc.subject.meshProstatic Neoplasms/*therapyen_GB
dc.titleGene therapy for prostate cancer.en_GB
dc.contributor.departmentCork Cancer Research Centre, Mercy University Hospital, Cork, Ireland., m.tangney@ucc.ieen_GB
dc.identifier.journalPostgraduate medicineen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.